Project Grant DP2EB041714
Award Date 9/30/26
Completion Date 7/31/31
Dollars Obligated $843K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded $528,000 to Sloan-Kettering Institute for Cancer Research on April 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate histone glycation as a dynamic epigenetic mark. The award funds research into non-enzymatic covalent modifications (NECMs) of histones, specifically glycation through methylglyoxal, a...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $752,280 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to decode basal cell multipotency as a precursor and therapeutic target in histological transformation across lung cancer subtypes. The award funds research into the molecular and cellular mechanisms driving adenocarcinoma transformation to small cell lung cancer or squamous cell carcinoma histology as a resistance mechanism...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Institutes of Health Office of the Director awarded Weill Medical College of Cornell University $1.185 million on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop an AI-human discovery engine for mechanistic cancer biology. The project builds, deploys, and benchmarks an agentic, closed-loop system that learns from human multi-omic datasets, constructs virtual-tumor foundation models to simulate cancer biology, and autonomously designs and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $731,937 on August 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and optimize computational immunology tools for predicting T-cell receptor specificity to peptide-major histocompatibility complex ligands. The project focuses on refining EnFoldX, an ensemble-based algorithm that leverages protein structure prediction models such as AlphaFold3 to jointly fold TCR:PMHC complexes and...
- The National Cancer Institute awarded New York Genome Center, Inc. $270,683 on May 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate Paired-Break-Seq, a single-cell multiomics sequencing technique for joint analysis of single-strand DNA breaks, double-strand DNA breaks, and transcriptome in cancer cells. The work addresses the technical gap in understanding how multiple types of DNA damage interact with gene regulation in heterogeneous tumor environments....
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Institute of General Medical Sciences awarded $534,644 to Sloan-Kettering Institute for Cancer Research on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the role of cohesin-STAG2 in R-loop homeostasis and its implications for cancer biology. The research dissects mechanisms underlying R-loop accumulation in STAG2-deficient cells, which frequently harbor mutations in cancer. The work will examine how loss of STAG2 (the most...